These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 18039573

  • 1. Antitumor effects of curcumin and structurally beta-diketone modified analogs on multidrug resistant cancer cells.
    Simoni D, Rizzi M, Rondanin R, Baruchello R, Marchetti P, Invidiata FP, Labbozzetta M, Poma P, Carina V, Notarbartolo M, Alaimo A, D'Alessandro N.
    Bioorg Med Chem Lett; 2008 Jan 15; 18(2):845-9. PubMed ID: 18039573
    [Abstract] [Full Text] [Related]

  • 2. Curcumin as a possible lead compound against hormone-independent, multidrug-resistant breast cancer.
    Labbozzetta M, Notarbartolo M, Poma P, Maurici A, Inguglia L, Marchetti P, Rizzi M, Baruchello R, Simoni D, D'Alessandro N.
    Ann N Y Acad Sci; 2009 Feb 15; 1155():278-83. PubMed ID: 19250217
    [Abstract] [Full Text] [Related]

  • 3. The antitumor activities of curcumin and of its isoxazole analogue are not affected by multiple gene expression changes in an MDR model of the MCF-7 breast cancer cell line: analysis of the possible molecular basis.
    Poma P, Notarbartolo M, Labbozzetta M, Maurici A, Carina V, Alaimo A, Rizzi M, Simoni D, D'Alessandro N.
    Int J Mol Med; 2007 Sep 15; 20(3):329-35. PubMed ID: 17671737
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Structure-activity relationship studies of curcumin analogues.
    Fuchs JR, Pandit B, Bhasin D, Etter JP, Regan N, Abdelhamid D, Li C, Lin J, Li PK.
    Bioorg Med Chem Lett; 2009 Apr 01; 19(7):2065-9. PubMed ID: 19249204
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Novel curcumin analogs targeting TNF-induced NF-kappaB activation and proliferation in human leukemic KBM-5 cells.
    Zambre AP, Kulkarni VM, Padhye S, Sandur SK, Aggarwal BB.
    Bioorg Med Chem; 2006 Nov 01; 14(21):7196-204. PubMed ID: 16843665
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antimicrobial and cytotoxic activity of agelasine and agelasimine analogs.
    Vik A, Hedner E, Charnock C, Tangen LW, Samuelsen Ø, Larsson R, Bohlin L, Gundersen LL.
    Bioorg Med Chem; 2007 Jun 15; 15(12):4016-37. PubMed ID: 17442577
    [Abstract] [Full Text] [Related]

  • 19. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.
    Cancer Chemother Pharmacol; 2009 Jun 15; 64(1):53-65. PubMed ID: 18931998
    [Abstract] [Full Text] [Related]

  • 20. SAR studies of brasilicardin A for immunosuppressive and cytotoxic activities.
    Komatsu K, Tsuda M, Tanaka Y, Mikami Y, Kobayashi J.
    Bioorg Med Chem; 2005 Mar 01; 13(5):1507-13. PubMed ID: 15698766
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.